RedHawk Appoints Florida Based Dolphin Medical as Exclusive SANDD™ Distributor for Five Gulf Coast States

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Under the Agreement, Dolphin has committed, among other things, to purchase annually from RedHawk for resale in the Territories, 6,000 SANDD mini™, SANDD HP™ or SANDD FR™ needle incineration devices, 2,000 SANDD Pro™ needle incineration devices and certain other medical supplies. The Agreement provides that RedHawk will sell the SANDD™ devices to Dolphin at list price less a customary distributor discount. Certain volume discounts are also available to Dolphin.

Sales to Dolphin commenced in March 2020 to assist RedHawk satisfy increased product demand.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.